The DOI matches its Crossref record; 670 of the 670 references it cites were found in a registry or an index.
Harnessing innate immune pathways for therapeutic advancement in cancer
Open accessAbstract
The innate immune pathway is receiving increasing attention in cancer therapy. This pathway is ubiquitous across various cell types, not only in innate immune cells but also in adaptive immune cells, tumor cells, and stromal cells. Agonists targeting the innate immune pathway have shown profound changes in the tumor microenvironment (TME) and improved tumor prognosis in preclinical studies. However, to date, the clinical success of drugs targeting the innate immune pathway remains limited. Interestingly, recent studies have shown that activation of the innate immune pathway can paradoxically promote tumor progression. The uncertainty surrounding the therapeutic effectiveness of targeted drugs for the innate immune pathway is a critical issue that needs immediate investigation. In this review, we observe that the role of the innate immune pathway demonstrates heterogeneity, linked to the tumor development stage, pathway status, and specific cell types. We propose that within the TME, the innate immune pathway exhibits multidimensional diversity. This diversity is fundamentally rooted in cellular heterogeneity and is manifested as a variety of signaling networks. The pro-tumor effect of innate immune pathway activation essentially reflects the suppression of classical pathways and the activation of potential pro-tumor alternative pathways. Refining our understanding of the tumor’s innate immune pathway network and employing appropriate targeting strategies can enhance our ability to harness the anti-tumor potential of the innate immune pathway and ultimately bridge the gap from preclinical to clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 401–600 of 670
Matsumoto, M., Tatematsu, M., Nishikawa, F., Azuma, M., Ishii, N., Morii-Sakai, A., Shime, H., & Seya, T. (2015) · Nature Communications · doi:10.1038/ncomms7280 · Cited by 130
Liu, R., Truax, A. D., Chen, L., Hu, P., Li, Z., Chen, J., Song, C., Chen, L., & Ting, J. P.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.5587 · Cited by 130
Kimura, Y., Inoue, A., Hangai, S., Saijo, S., Negishi, H., Nishio, J., Yamasaki, S., Iwakura, Y., Yanai, H., & Taniguchi, T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617903113 · Cited by 130
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
Liu, X., Liu, L., Ren, Z., Yang, K., Xu, H., Luan, Y., Fu, K., Guo, J., Peng, H., Zhu, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.062 · Cited by 130
Modulation of T‐cell function by type I interferon
Tough, D. F. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.7 · Cited by 129
Jin, S., Li, M. K., Chang, H., Wang, R., Zhang, Z., Zhang, J., He, Y., & Ma, H. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01572-2 · Cited by 128
Sun, Y., Hu, H., Liu, Z., Xu, J., Gao, Y., Zhan, X., Zhou, S., Zhong, W., Wu, D., Wang, P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006481 · Cited by 128
The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING–IFN-β pathway
Takahashi, M., Lio, C. J., Campeau, A., Steger, M., Ay, F., Mann, M., Gonzalez, D. J., Jain, M., & Sharma, S. (2021) · Nature Immunology · doi:10.1038/s41590-021-00896-3 · Cited by 126
Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma
Xuan, W., Hsu, W.-H., Khan, F., Dunterman, M., Pang, L., Wainwright, D. A., Ahmed, A. U., Heimberger, A. B., Lesniak, M. S., & Chen, P. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0559 · Cited by 126
NOD2 Suppresses Colorectal Tumorigenesis via Downregulation of the TLR Pathways
Udden, S. M. N., Peng, L., Gan, J., Shelton, J. M., Malter, J. S., Hooper, L. V., & Zaki, H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.084 · Cited by 124
Targeting Toll-Like Receptors for Cancer Therapy
Braunstein, M. J., Kucharczyk, J. R., & Adams, S. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0589-7 · Cited by 122
Nod1-dependent control of tumor growth
Correia, J. D. S., Miranda, Y., Austin-Brown, N., Hsu, J. C., Mathison, J. C., Xiang, R., Zhou, H., Li, Q., Han, J., & Ulevitch, R. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509228103 · Cited by 121
Wang, B., Tang, M., Yuan, Z., Li, Z., Hu, B., Bai, X., Chu, J., Xu, X., & Zhang, X.-Q. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.02.026 · Cited by 121
Accolla, R. S., Ramia, E., Tedeschi, A., & Forlani, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01806 · Cited by 120
Glycolysis drives STING signaling to facilitate dendritic cell antitumor function
Hu, Z., Yu, X., Ding, R., Liu, B., Gu, C., Pan, X., Han, Q., Zhang, Y., Wan, J., Cui, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166031 · Cited by 120
Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome
Du, Q., Wang, Q., Fan, H., Wang, J., Liu, X., Wang, H., Wang, Y., & Hu, R. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.017 · Cited by 118
Wang, H., Wang, Y., Du, Q., Lü, P., Fan, H., Lu, J., & Hu, R. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.03.009 · Cited by 117
Li, T., Fu, B., Zhang, X., Zhou, Y., Yang, M., Cao, M., Chen, Y., Tan, Y., & Hu, R. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-1043 · Cited by 117
Schenten, D., Nish, S. A., Yu, S., Yan, X., Lee, H. K., Brodsky, I. E., Pasman, L., Yordy, B., Wunderlich, F. T., Brüning, J. C., et al. (2014) · Immunity · doi:10.1016/j.immuni.2013.10.023 · Cited by 116
NLRP3 inflammasomes in macrophages drive colorectal cancer metastasis to the liver
Deng, Q., Geng, Y., Zhao, L., Li, R., Zhang, Z., Li, K., Liang, R., Shao, X., Huang, M., Zuo, D., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.030 · Cited by 116
Nierkens, S., den Brok, M. H., Garcia, Z., Togher, S., Wagenaars, J. A. L., Wassink, M., Boon, L., Ruers, T. J. M., Figdor, C. G., Schoenberger, S. P., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2154 · Cited by 114
Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation
Zhang, C.-X., Huang, D.-J., Baloche, V. M. D., Zhang, L., Xu, J.-X., Li, B., Zhao, X., He, J., Mai, H., Chen, Q., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-00248-0 · Cited by 114
Dai, J., Qu, T., Yin, D., Cui, Y., Zhang, C., Zhang, E., & Guo, R. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05840-x · Cited by 114
Chatterjee, S., Crozet, L., Damotte, D., Iribarren, K., Schramm, C., Alifano, M., Mansuet‐Lupo, A., Cherfils‐Vicini, J., Goc, J., Katsahian, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2698 · Cited by 113
Jia, D., Yang, W., Li, L., Liu, H., Tan, Y., Ooi, S., Chi, L., Filion, L. G., Figeys, D., & Wang, L. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.145 · Cited by 113
Ferris, R. L., Saba, N. F., Gitlitz, B. J., Haddad, R. I., Sukari, A. W., Neupane, P. C., Morris, J. C., Misiukiewicz, K. J., Bauman, J. E., Fenton, M. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1888 · Cited by 113
Butowski, N. A., Chang, S. M., Junck, L., DeAngelis, L. M., Abrey, L. E., Fink, K., Cloughesy, T. F., Lamborn, K. R., Salazar, A. Μ., & Prados, M. D. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9693-3 · Cited by 112
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
Friedrich, M., Hahn, M., Michel, J., Sankowski, R., Kilian, M., Kehl, N., Günter, M., Bunse, T., Pusch, S., von Deimling, A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac138 · Cited by 112
Fang, C., Mo, F., Liu, L., Du, J., Luo, M., Men, K., Na, F., Wang, W., Yang, H., & Wei, X. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0456-1 · Cited by 111
Self-citationGao, Y., Zheng, X., Chang, B., Lin, Y., Huang, X., Wang, W., Ding, S., Zhan, W., Wang, S., Xiao, B.-B., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00731-w · Cited by 111
Effect of Vascular Endothelial Growth Factor and FLT3 Ligand on Dendritic Cell Generation In Vivo
Ohm, J. E., Shurin, M. R., Esche, C., Lotze, M. T., Carbone, D. P., & Gabrilovich, D. I. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.6.3260 · Cited by 110
Zhou, Y., Hu, L., Tang, W., Li, D., Ma, L., Liu, H., Zhang, S., Zhang, X., Dong, L., Chen, S., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01028-4 · Cited by 110
Karki, R., Malireddi, R. K. S., Zhu, Q., & Kanneganti, T. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1317414 · Cited by 109
The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma
Thomsen, M. K., Skouboe, M. K., Boularan, C., Vernejoul, F., Lioux, T., Leknes, S. L., Berthelsen, M. F., Riedel, M., Cai, H., Joseph, J. V., et al. (2019) · Oncogene · doi:10.1038/s41388-019-1108-8 · Cited by 109
STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability
Rañoa, D. R. E., Widau, R. C., Mallon, S., Parekh, A. D., Nicolae, C. M., Huang, X., Bolt, M. J., Arina, A., Parry, R., Kron, S. J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1972 · Cited by 108
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Kitajima, S., Tani, T., Springer, B. F., Campisi, M., Osaki, T., Haratani, K., Chen, M., Knelson, E. H., Mahadevan, N. R., Ritter, J., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.015 · Cited by 107
Takemura, R., Takaki, H., Okada, S., Shime, H., Akazawa, T., Oshiumi, H., Matsumoto, M., Teshima, T., & Seya, T. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0219 · Cited by 105
Mercier, B. C., Cottalorda, A., Coupet, C., Marvel, J., & Bonnefoy, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801167 · Cited by 103
Brackett, C. M., Kojouharov, B., Veith, J. M., Greene, K. F., Burdelya, L. G., Gollnick, S. O., Abrams, S. I., & Gudkov, A. V. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521359113 · Cited by 103
Cytosolic Antiviral RNA Recognition Pathway Activates Caspases 1 and 3
Rintahaka, J., Wiik, D., Kovanen, P. E., Alenius, H. T., & Matikainen, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1749 · Cited by 102
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
Salazar, L. G., Lu, H., Reichow, J. L., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6007 · Cited by 101
Yang, X. Q., Feng, W., Wang, R., Yang, F., Wang, L., Chen, S., Ru, Y., Cheng, T., & Zheng, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1412910 · Cited by 101
Low, J., Chandramohan, V., Bowie, M. L., Brown, M. C., Waitkus, M. S., Briley, A., Stevenson, K., Fuller, R., Reitman, Z. J., Muscat, A. M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.009 · Cited by 101
STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer
Da, Y., Liu, Y., Hu, Y., Liu, W., Ma, J., Lü, N., Zhang, C., & Zhang, C. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2054105 · Cited by 101
Cheng, H.-Y., Hsieh, C.-H., Lin, P., Chen, Y.-T., Hsu, D. S., Tai, S., Chu, P., & Yang, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004832 · Cited by 101
Guo, H., Chen, Y., Hu, X., Qian, G., Ge, S., & Zhang, J. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-77 · Cited by 100
Sabado, R. L., Pavlick, A. C., Gnjatic, S., Cruz, C. M., Vengco, I., Hasan, F., Spadaccia, M. R., Darvishian, F., Chiriboga, L. A., Holman, R. M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0202 · Cited by 100
Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA
Shih, A. Y., Damm‐Ganamet, K. L., & Mirzadegan, T. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.10.027 · Cited by 99
Furukawa, S., Saito, H., Inoue, T., Matsuda, T., Fukatsu, K., Han, I., Ikeda, S., & Hidemura, A. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00228-8 · Cited by 98
Wu, Y., Wu, J., Chen, T., Li, Q., Peng, W., Li, H., Tang, X., & Fu, X. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-4999-2 · Cited by 98
Schmoll, H., Wittig, B., Arnold, D., Riera‐Knorrenschild, J., Nitsche, D., Kroening, H., Mayer, F., Andel, J., Ziebermayr, R., & Scheithauer, W. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1682-7 · Cited by 97
Cho, J., Lee, H.-J., Ko, H., Yoon, B.-I., Choe, J., Kim, K., Hahn, T., Han, J. A., Choi, S. S., Jung, Y. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15326 · Cited by 97
The AIM2 and NLRP3 inflammasomes trigger IL-1–mediated antitumor effects during radiation
Han, C., Godfrey, V., Liu, Z., Han, Y., Liu, L., Peng, H., Weichselbaum, R. R., Zaki, H., & Fu, Y. (2021) · Science Immunology · doi:10.1126/sciimmunol.abc6998 · Cited by 97
TLR/NCR/KIR: Which One to Use and When?
Sivori, S., Carlomagno, S., Pesce, S., Moretta, A., Vitale, M., & Marcenaro, E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00105 · Cited by 96
Nierkens, S., den Brok, M. H., Roelofsen, T., Wagenaars, J. A. L., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008368 · Cited by 95
Optimal multivalent targeting of membranes with many distinct receptors
Curk, T., Dobnikar, J., & Frenkel, D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704226114 · Cited by 95
Grimmig, T., Matthes, N., Hoeland, K. M., Tripathi, S., Chandraker, A. K., Grimm, M. R., Moench, R., Moll, E.-M., Friess, H., Tsaur, I., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3069 · Cited by 93
Single chromosomal gains can function as metastasis suppressors and promoters in colon cancer
Vasudevan, A., Baruah, P., Smith, J. C., Wang, Z.-H., Sayles, N. M., Andrews, P. A., Kendall, J., Leu, J., Chunduri, N. K., Levy, D., et al. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.01.034 · Cited by 93
Haase, S., Banerjee, K., Mujeeb, A., Hartlage, C. S., Núñez, F. M., Núñez, F. J., Alghamri, M. S., Kadiyala, P., Carney, S. V., Barissi, M. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154229 · Cited by 93
Chew, V., Tow, C., Huang, C. W., Bard-Chapeau, E. A., Copeland, N. G., Jenkins, N. A., Weber, A., Lim, K. H., Toh, H. C., Heikenwälder, M. F., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs436 · Cited by 92
Sun, J., Yang, M., Ban, Y., Gao, W., Song, B., Wang, Y., Zhang, Y., Shao, Q., Kong, B., & Qu, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147186 · Cited by 92
Spinetti, T., Spagnuolo, L., Mottas, I., Secondini, C., Treinies, M., Rüegg, C., Hotz, C., & Bourquin, C. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1230578 · Cited by 92
Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses
Jiang, X., Muthusamy, V., Fedorova, O., Kong, Y., Kim, D. J., Bosenberg, M., Pyle, A. M., & Iwasaki, A. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190801 · Cited by 92
Lin, A., Wang, G., Zhao, H., Zhang, Y., Han, Q., Zhang, C., Tian, Z., & Zhang, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1074376 · Cited by 91
Francica, B. J., Ghasemzadeh, A., Desbien, A. L., Theodros, D., Sivick, K. E., Reiner, G. L., Glickman, L. H., Marciscano, A. E. E., Sharabi, A. B., Leong, M. L. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0263 · Cited by 91
Nucleic Acid Sensors and Programmed Cell Death
Maelfait, J., Liverpool, L., & Rehwinkel, J. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.11.016 · Cited by 91
Remodeling oncogenic transcriptomes by small molecules targeting NONO
Kathman, S. G., Koo, S. J., Lindsey, G. L., Her, H.-L., Blue, S. M., Li, H., Jaensch, S., Remsberg, J. R., Ahn, K., Yeo, G. W.-M., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01270-0 · Cited by 90
DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs
Guo, H., Vuille, J. A., Wittner, B. S., Lachtara, E. M., Hou, Y., Lin, M., Zhao, T., Raman, A. T., Russell, H. C., Reeves, B. A., et al. (2023) · Cell · doi:10.1016/j.cell.2023.05.028 · Cited by 90
Activation of Tumor-Cell STING Primes NK-Cell Therapy
Knelson, E. H., Ivanova, E. V., Tarannum, M., Campisi, M., Lizotte, P. H., Booker, M. A., Ozgenc, I., Noureddine, M., Meisenheimer, B., Chen, M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0017 · Cited by 88
Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases
Patra, M. C., Shah, M., & Choi, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.002 · Cited by 88
Cao, L., Liu, S., Li, Y., Yang, G., Luo, Y., Li, S., Du, H., Zhao, Y., Wang, D., Chen, J., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.010 · Cited by 88
Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome
Pimenta, M. G., Otero, Á., Guzmán, D. Á. A., Argente, D. P., Martín, L. R., Sousa-Casasnovas, P., García-Martín, A., de Oca, J. C. R. M., Ledezma, J. J. V., Carretero, L. T., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12927 · Cited by 88
Eissmann, P., Evans, J. H., Mehrabi, M., Rose, E. L., Nedvetzki, S., & Davis, D. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903985 · Cited by 87
Bourquin, C., Hotz, C., Noerenberg, D., Voelkl, A., Heidegger, S. M., Roetzer, L. C., Storch, B., Sandholzer, N., Wurzenberger, C., Anz, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3903 · Cited by 86
Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 86
Takashima, Y., Kawaguchi, A., Kanayama, T., Hayano, A., & Yamanaka, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24897 · Cited by 86
Jiang, Y., Zhou, J., Luo, P., Gao, H., Ma, Y., Chen, Y.-S., Li, L., Zou, D., Zhang, Y., & Jing, Z. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.053 · Cited by 86
NONO and tumorigenesis: More than splicing
Feng, P., Li, L., Deng, T., Liu, Y., Ling, N., Qiu, S., Zhang, L., Peng, B., Xiong, W., Cao, L., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15141 · Cited by 86
Lutz, V., Hellmund, V. M., Picard, F. S. R., Raifer, H., Ruckenbrod, T., Klein, M., Bopp, T., Savai, R., Duewell, P., Keber, C. U., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0398 · Cited by 86
Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment
Mertens, C., Mora, J., Ören, B., Grein, S., Winslow, S., Scholich, K., Weigert, A., Malmström, P., Forsare, C., Fernö, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1408751 · Cited by 85
Ni, H., Zhang, H., Li, L., Huang, H., Guo, H., Zhang, L., Li, C., Xu, J.-X., Nie, C.-P., Li, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005151 · Cited by 85
Nrf2 suppresses the function of dendritic cells to facilitate the immune escape of glioma cells
Wang, J., Liu, P., Xin, S., Wang, Z., & Li, J. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.07.031 · Cited by 84
Zheng, Z., Jia, S., Shao, C., & Shi, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2546-5 · Cited by 84
Mertens, C., Akam, E. A., Rehwald, C., Brüne, B., Tomat, E., & Jung, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166164 · Cited by 83
Binker-cosen, M. J., Richards, D., Oliver, B., Gaisano, H. Y., Binker, M. G., & Cosen-Binker, L. I. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.051 · Cited by 82
Siglec‐h on activated microglia for recognition and engulfment of glioma cells
Kopatz, J., Beutner, C., Welle, K., Bodea, L., Reinhardt, J., Claude, J., Linnartz‐Gerlach, B., & Neumann, H. (2013) · Glia · doi:10.1002/glia.22501 · Cited by 81
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer
Tuomela, J. M., Sandholm, J. A., Karihtala, P., Ilvesaro, J. M., Vuopala, K. S., Kauppila, J. H., Kauppila, S., Chen, D., Pressey, C. S., Härkönen, P. L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2181-7 · Cited by 81
McCarron, M. J., & Reen, D. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.55 · Cited by 80
Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity
Uto, T., Fukaya, T., Takagi, H., Arimura, K., Nakamura, T., Kojima, N., MALISSEN, B., & Sato, K. (2016) · Nature Communications · doi:10.1038/ncomms11273 · Cited by 80
Thomas, M., Ponce-Aix, S., Navarro, A., Riera‐Knorrenschild, J., Schmidt, M., Wiegert, E., Kapp, K., Wittig, B., Mauri, C., Gómez, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy326 · Cited by 80
BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells
Combes, A. J., Camosseto, V., N’guessan, P., Argüello, R. J., Mussard, J., Caux, C., Bendriss‐Vermare, N., Pierre, P., & Gatti, E. (2017) · Nature Communications · doi:10.1038/s41467-017-00695-1 · Cited by 79
Bourquin, C., Pommier, A., & Hotz, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.001 · Cited by 79
Epithelial NAIPs protect against colonic tumorigenesis
Allam, R., Maillard, M. H., Tardivel, A., Chennupati, V., Bega, H., Yu, E. C.-W., Velin, D., Schneider, P., & Maslowski, K. M. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20140474 · Cited by 78
Moore, J. A., Mistry, J. J., Hellmich, C., Horton, R. H., Wojtowicz, E. E., Jibril, A., Jefferson, M., Wileman, T. E., Beraza, N., Bowles, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153157 · Cited by 77
Sivori, S., Carlomagno, S., Moretta, L., & Moretta, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200535781 · Cited by 76
Heat shock protein vaccines against glioblastoma: from bench to bedside
Ampie, L., Choy, W., Lamano, J. B., Fakurnejad, S., Bloch, O. G., & Parsa, A. T. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1837-7 · Cited by 75
Smith, D. A. B., Conkling, P., Richards, D., Nemunaitis, J. J., Boyd, T. E., Mita, A. C., Bourdonnaye, G. D. L., Wages, D. S., & Bexon, A. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1547-6 · Cited by 75
TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients
Wang, C., Cao, S., Yan, Y., Ying, Q., Jiang, T., Xu, K., & Wu, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-415 · Cited by 75
Baird, J. R., Bell, R. B., Troesch, V., Friedman, D. J., Bambina, S., Kramer, G. F., Blair, T. C., Medler, T. R., Wu, Y., Sun, Z., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1652 · Cited by 75
Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
Poon, C. C., Gordon, P. M. K., Liu, K., Yang, R., Sarkar, S., Mirzaei, R., Ahmad, S. T., Hughes, M. L., Yong, V. W., & Kelly, J. J. (2019) · Oncotarget · doi:10.18632/oncotarget.26863 · Cited by 75
TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
Li, S., Sun, R., Chen, Y., Wei, H., & Tian, Z. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2371 · Cited by 74
Arterbery, A. S., Osafo-Addo, A. D., Avitzur, Y., Ciarleglio, M. M., Deng, Y., Lobritto, S., Martínez, M., Hafler, D. A., Kleinewietfeld, M., & Ekong, U. D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502276 · Cited by 74
Encapsulation and delivery of phage as a novel method for gut flora manipulation in situ: A review
Yang, Y., Du, H., Zou, G., Song, Z., Zhou, Y., Li, H., Tan, C. S., Chen, H., Fischetti, V. A., & Li, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.048 · Cited by 74
Xu, R., Wu, M., Liu, S., Shang, W., Li, R., Xu, J., Huang, L., & Wang, F. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03272-5 · Cited by 73
Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma
Kauppila, J. H., Takala, H., Selander, K. S., Lehenkari, P. P., Saarnio, J., & Karttunen, T. J. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03991.x · Cited by 72
Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils
Zhang, H., Zhu, X., Friesen, T. J., Kwak, J., Pisarenko, T., Mekvanich, S., Velasco, M. A., Randolph, T. W., Kargl, J., & Houghton, A. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153643 · Cited by 72
Functional TLR5 Genetic Variants Affect Human Colorectal Cancer Survival
Klimosch, S. N., Försti, A., Eckert, J., Knežević, J., Bevier, M., Schönfels, W. V., Heits, N., Walter, J., Hinz, S., Lascorz, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1746 · Cited by 71
Weihrauch, M. R., Richly, H., von Bergwelt‐Baildon, M. S., Becker, H., Schmidt, M., Hacker, U. T., Shimabukuro‐Vornhagen, A., Holtick, U., Nokay, B., Schroff, M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.002 · Cited by 70
Toll-Like Receptors in Angiogenesis
Grote, K., Schütt, H., & Schieffer, B. (2011) · The Scientific World JOURNAL · doi:10.1100/tsw.2011.92 · Cited by 70
ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade
Liu, X., Cen, X., Wu, R., Chen, Z., Xie, Y., Wang, F., Shan, B., Zeng, L., Zhou, J., Xie, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39920-5 · Cited by 70
Chow, S. C., Gowing, S. D., Cools‐Lartigue, J., Chen, C. B., Bérubé, J., Yoon, H., Chan, C. H. F., Rousseau, M., Bourdeau, F., Giannias, B., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29111 · Cited by 69
Eiró, N., Altadill, A., Salcedo, L. M. J., Rodríguez, M., González, L. O., Atienza, S., Bermúdez, S., Fernández‐García, B., Fresno-Forcelledo, M. F., Rodrigo, L., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12180 · Cited by 69
Yin, X., Zhang, Q., Chen, Z., Wang, H., Li, X., Wang, H., Li, H., Kang, C., Chu, S., Li, K., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4480 · Cited by 69
Zhong, M., Zhong, C. F., Cui, W., Wang, G., Zheng, G., Li, L., Zhang, J., Ren, R., Gao, H., Wang, T., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5670-9 · Cited by 69
Such, L., Zhao, F., Liu, D. H., Thier, B., Le‐Trilling, V. T. K., Sucker, A., Coch, C., Pieper, N., Howe, S., Bhat, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131572 · Cited by 68
Catania, G., Rodella, G., Vanvarenberg, K., Véronique Préat, A., & Malfanti, A. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122006 · Cited by 68
Shiraki (1992) · International Journal of Oncology · doi:10.3892/ijo_00000080 · Cited by 67
Activation of the pattern recognition receptor NOD1 augments colon cancer metastasis
Jiang, H. Y., Najmeh, S., Martel, G., MacFadden-Murphy, E., Farias, R., Savage, P., Leone, A., Roussel, L., Cools‐Lartigue, J., Gowing, S. D., et al. (2020) · Protein & Cell · doi:10.1007/s13238-019-00687-5 · Cited by 67
Fan, J.-B., Miyauchi, S., Xu, H., Liu, D., Kim, L. J. Y., Burkart, C., Cheng, H., Arimoto, K., Yan, M., Zhou, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0608 · Cited by 67
Hirano, R., Okamoto, K., Shinke, M., Sato, M., Watanabe, S., Watanabe, H., Kondoh, G., Kadonosono, T., & Kizaka‐Kondoh, S. (2023) · Communications Biology · doi:10.1038/s42003-023-04525-7 · Cited by 67
Pimentel‐Nunes, P., Gonçalves, N., Boal‐Carvalho, I., Afonso, L. P., Lopes, P., Roncon‐Albuquerque, R., Henrique, R., Moreira‐Dias, L., Leite-Moreira, A. F., & Dinis-Ribeiro, M. J. (2012) · Helicobacter · doi:10.1111/hel.12008 · Cited by 66
Bufalieri, F., Caimano, M., Severini, L. L., Basili, I., Paglia, F., Sampirisi, L., Loricchio, E., Petroni, M., Canettieri, G., Santoro, A., et al. (2020) · Cancers · doi:10.3390/cancers12020321 · Cited by 66
Ka, N., Lim, G. Y., Hwang, S., Kim, S.-S., & Lee, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110138 · Cited by 66
Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
Yang, Y., Li, H., Fotopoulou, C., Cunnea, P., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049340 · Cited by 66
Wang, Z., Yan, J., Lin, H., Hua, F., Wang, X., Liu, H., Lv, X., Yu, J., Mi, S., Wang, J., et al. (2013) · Hepatology · doi:10.1002/hep.26234 · Cited by 65
Self-citationCD31 is a key coinhibitory receptor in the development of immunogenic dendritic cells
Clément, M., Fornasa, G., Guedj, K., Mkaddem, S. B., Gaston, A., Khallou‐Laschet, J., Morvan, M., Nicoletti, A., & Caligiuri, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314505111 · Cited by 65
Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice
Lai, J., Fu, Y., Tian, S., Huang, S., Luo, X., Lin, L., Zhang, X., Wang, H., Lin, Z., Zhao, H., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.005 · Cited by 65
Low NLRP3 expression predicts a better prognosis of colorectal cancer
Shi, F., Wei, B., Lan, T., Xiao, Y., Quan, X., Chen, J., Zhao, C., & Gao, J. (2021) · Bioscience Reports · doi:10.1042/bsr20210280 · Cited by 65
Theivanthiran, B., Yarla, N. S., Haykal, T., Nguyen, Y., Cao, L., Ferreira, M., Holtzhausen, A., Al-Rohil, R. N., Salama, A. K. S., Beasley, G. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq7019 · Cited by 65
Schölch, S., Rauber, C., Tietz, A., Rahbari, N. N., Bork, U., Schmidt, T., Kahlert, C., Haberkorn, U., Tomai, M. A., Lipson, K. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3081 · Cited by 64
T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells
Nouri, Y., Weinkove, R., & Perret, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003065 · Cited by 64
Ying, J., Zhou, H., Liu, P., You, Q., Kuang, F. L., Shen, Y., & Hu, Z. (2018) · Cell & Bioscience · doi:10.1186/s13578-017-0198-7 · Cited by 63
Liu, W.-T., Jing, Y.-Y., Gao, L., Li, R., Yang, X., Pan, X.-R., Yang, Y., Meng, Y., Hou, X.-J., Zhao, Q.-D., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0340-7 · Cited by 63
Endothelial STING controls T cell transmigration in an IFNI-dependent manner
Anastasiou, M., Newton, G. A., Kaur, K., Carrillo-Salinas, F. J., Smolgovsky, S. A., Bayer, A. L., Ilyukha, V., Sharma, S., Poltorak, A., Luscinskas, F. W., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.149346 · Cited by 62
Gu, Y., Yang, H. J., He, C., Zhao, T., Lu, R., Liu, J., Mo, X., Wen, F., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01479-4 · Cited by 62
Self-citationCombination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
Go, E.-J., Yang, H., Chon, H. J., Yang, D. S., Ryu, W., Kim, D., Han, D. K., Kim, C., & Park, W. (2020) · Cancers · doi:10.3390/cancers12113123 · Cited by 61
Self-citationZhou, Y., Guo, Y., Chen, L., Zhang, X., Wu, W., Zhi-min, Y., Li, X., Wang, Y., Hu, Z., & Wang, Z. (2022) · Theranostics · doi:10.7150/thno.73104 · Cited by 61
NLRP3 inflammasome activation plays a carcinogenic role through effector cytokine IL-18 in lymphoma
Zhao, X., Zhang, C., Hua, M., Wang, R., Zhong, C., Yu, J., Han, F., He, N., Zhao, Y., Liu, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21010 · Cited by 60
Xie, X., Ma, L., Zhou, Y., Shen, W., Xu, D., Dou, J., Shen, B., & Zhou, C. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115223 · Cited by 60
Mitchell, W. M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1172960 · Cited by 57
miR‐545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG‐I
Song, B., Ji, W., Guo, S., Liu, A., Jing, W., Shao, C., Li, G., & Jin, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.10.004 · Cited by 57
The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma
Kachler, K., Holzinger, C., Trufa, D. I., Sîrbu, H., & Finotto, S. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1456612 · Cited by 57
Ruzicka, M., König, L. M., Formisano, S., Boehmer, D. F. R., Vick, B., Heuer, E.-M., Meinl, H., Kocheise, L., Zeitlhoefler, M., Ahlfeld, J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0639-x · Cited by 57
Long, F., Lin, H., Zhang, X., Zhang, J., Xiao, H., & Wang, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.598939 · Cited by 57
Self-citationMetabolic regulation on the immune environment of glioma through gut microbiota
Lyu, Y., Yang, H., & Liang, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.005 · Cited by 57
Self-citationLan, F., Yue, X., Ren, G., Li, H., Li, P., Wang, Y., & Xia, T. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.09.021 · Cited by 56
Udumula, M. P., Sakr, S., Dar, S. A., Alvero, A. B., Ali‐Fehmi, R., Abdulfatah, E., Li, J., Jiang, J., Tang, A., Buekers, T., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101272 · Cited by 56
Patel, S. P., Petroni, G. R., Roszik, J., Olson, W. C., Wages, N. A., Chianese‐Bullock, K. A., Smolkin, M. E., Varhegyi, N., Gaughan, E. M., Smith, K. T., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003220 · Cited by 56
Shi, J., Liu, C., Luo, S., Cao, T., Lin, B., Zhou, M., Zhang, X., Wang, S., Zheng, T., & Li, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104384 · Cited by 55
Structural Mechanisms in NLR Inflammasome Assembly and Signaling
Hu, Z., & Chai, J. (2016) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-41171-2_2 · Cited by 54
T lymphocytes as dynamic regulators of glioma pathobiology
Cordell, E., Alghamri, M. S., Castro, M. G., & Gutmann, D. H. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac055 · Cited by 54
Wei, X., Ye, J., Pei, Y., Wang, C., Yang, H., Tian, J., Si, G., Ma, Y., Wang, K., & Liu, G. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12264 · Cited by 53
Self-citationNLRP3 inflammasome-induced pyroptosis in digestive system tumors
Wen, J., Xuan, B., Liu, Y., Wang, L., He, L., Meng, X., Zhou, T., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1074606 · Cited by 53
Wei, K., Zhang, H., Yang, S., Cui, Y., Zhang, B., Liu, J., Tang, L. V., Tan, Y., Liu, S., Chen, S., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01212-7 · Cited by 52
Belmont, L., Rabbe, N., Antoine, M., Cathelin, D., Guignabert, C., Kurie, J. M., Cadranel, J. L., & Wislez, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28413 · Cited by 51
RIG-I Modulates Src-Mediated AKT Activation to Restrain Leukemic Stemness
Li, X.-Y., Jiang, L., Chen, L., Ding, M., Guo, H., Zhang, W., Zhang, H., Ma, X., Liu, X.-Z., Xi, X., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.12.008 · Cited by 51
Getting TANned: How the tumor microenvironment drives neutrophil recruitment
SenGupta, S., Subramanian, B. C., & Parent, C. A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ri0718-282r · Cited by 51
Role of Imiquimod in Skin Cancer Treatment
Urosevic, M., & Dummer, R. (2004) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200405060-00010 · Cited by 50
Gadkaree, S. K., Fu, J. L., Sen, R., Korrer, M. J., Allen, C. T., & Kim, Y. J. (2017) · Head & Neck · doi:10.1002/hed.24704 · Cited by 50
Lin, W., Zhao, Z., Ni, Z., Zhao, Y., Du, W., & Chen, S. (2017) · Cell Proliferation · doi:10.1111/cpr.12392 · Cited by 49
Dajon, M., Iribarren, K., Petitprez, F., Marmier, S., Mansuet‐Lupo, A., Gillard, M., Ouakrim, H., Victor, N., Bartolo, V. D., Joubert, P.-E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1505174 · Cited by 49
Huang, Y., Zhang, Q., Lubas, M., Yang, Y., Yalçın, F., Efe, I. E., Xia, P., Motta, E., Buonfiglioli, A., Lehnardt, S., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0666-20.2020 · Cited by 49
Hu, X., Fatima, S., Chen, M., Xu, K., Huang, C., Gong, R., Su, T., Wong, H. L. X., Bian, Z., & Kwan, H. Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04076-x · Cited by 49
PP2Ac/STRN4 negatively regulates STING-type I IFN signaling in tumor-associated macrophages
Ho, W. S., Mondal, I., Xu, B., Das, O., Sun, R., Chiou, P., Cai, X., Tahmasebinia, F., McFadden, E., Wu, C. Y.-J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162139 · Cited by 49
Li, Y., Shi, Y., McCaw, L., Li, Y., Zhu, F., Gorczynski, R., Duncan, G. S., Yang, B. B., Ben‐David, Y., & Spaner, D. (2015) · Blood · doi:10.1182/blood-2014-12-618678 · Cited by 48
Pillars Article: M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J. Immunol. 2000. 164: 6166–6173
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701141 · Cited by 48
STING regulates BCR signaling in normal and malignant B cells
Tang, C.-H. A., Lee, A. C., Chang, S., Xu, Q. S., Shao, A., Lo, Y., Spalek, W. T., Pinilla-Ibarz, J. A., Valle, J. R. D., & Hu, C. A. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00552-0 · Cited by 48
Cohen, E. E. W., Nabell, L., Wong, D. J., Day, T., Daniels, G. A., Milhem, M. M., Deva, S., Jameson, M. B., Guntinas-Lichius, O., Almubarak, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1411 · Cited by 48
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy
Lorenzo, A. D., Bolli, E., Ruiu, R., Ferrauto, G., Gregorio, E. D., Avalle, L., Savino, A., Poggio, P., Merighi, I. F., Riccardo, F., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2086752 · Cited by 48
Duewell, P., Beller, E., Kirchleitner, S. V., Adunka, T., Bourhis, H., Siveke, J. T., Mayr, D. C., Kobold, S., Endres, S., & Schnurr, M. M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1029698 · Cited by 47
Han, S., Wang, C., Qin, X., Xia, J., & Wu, A. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0552-y · Cited by 47
Xiang, W., Shi, R., Zhang, D., Kang, X., Zhang, L., Yuan, J., Zhang, X., & Miao, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00327-z · Cited by 47
Jeong, S., Yang, M. J., Choi, S., Kim, J., & Koh, G. Y. (2021) · Nature Communications · doi:10.1038/s41467-021-24603-w · Cited by 47
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis
Guillerey, C., Chow, M. T., Miles, K. M., Olver, S. D., Sceneay, J., Takeda, K., Möller, A., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027468 · Cited by 46
Yang, H., Brackett, C. M., Morales-Tirado, V. M., Li, Z., Zhang, Q., Wilson, M. W., Benjamin, C. A., Harris, W. B., Waller, E. K., Gudkov, A. V., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6500 · Cited by 45
Self-citationKnarr, M., Avelar, R. A., Sekhar, S. C., Kwiatkowski, L. J., Dziubinski, M. L., McAnulty, J., Skala, S. L., Avril, S., Drapkin, R., & DiFeo, A. V. (2020) · Nature Communications · doi:10.1038/s41467-020-17030-w · Cited by 45
RIG-I–Like Receptor LGP2 Is Required for Tumor Control by Radiotherapy
Zheng, W., Rañoa, D. R. E., Huang, X., Hou, Y., Yang, K., Poli, E. C., Beckett, M. A., Fu, Y., & Weichselbaum, R. R. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2324 · Cited by 45
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis
Li, Z., Zhou, Y., Jia, K., Yang, Y., Zhang, L., Wang, S., Dong, Y., Wang, M., Li, Y., Lu, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01381-6 · Cited by 45
DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells
Tuomela, J. M., Sandholm, J. A., Kaakinen, M., Patel, A. K., Kauppila, J. H., Ilvesaro, J. M., Chen, D., Harris, K. W., Graves, D. E., & Selander, K. S. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2762-0 · Cited by 44
Grauer, O. M., Pöschl, P., Lohmeier, A., Adema, G. J., & Bogdahn, U. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9274-2 · Cited by 44
Nod1 Limits Colitis-Associated Tumorigenesis by Regulating IFN-γ Production
Zhan, Y., Seregin, S. S., Chen, J., & Chen, G. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501822 · Cited by 44
Qin, Y., Chen, W., Jiang, G., Zhou, L., Yang, X., Li, H., He, X., Wang, H., Zhou, Y., Huang, S., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw9960 · Cited by 44
Pimentel‐Nunes, P., Gonçalves, N., Boal‐Carvalho, I., Afonso, L. P., Lopes, P., Roncon‐Albuquerque, R., Soares, J., Cardoso, E., Henrique, R., Moreira‐Dias, L., et al. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200567 · Cited by 42
Huang, H., Cai, B., Suen, C., Lee, H.-Y., Hwang, M., Liu, F., & Kannagi, R. (2020) · Cells · doi:10.3390/cells9020397 · Cited by 41
Burassakarn, A., Srisathaporn, S., Pientong, C., Wongjampa, W., Vatanasapt, P., Patarapadungkit, N., & Ekalaksananan, T. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105279 · Cited by 41
Dietsch, G. N., Randall, T. D., Gottardo, R., Northfelt, D., Ramanathan, R. K., Cohen, P. A., Manjarrez, K. L., Newkirk, M., Bryan, J. K., & Hershberg, R. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0578 · Cited by 40
Yu, X., Wang, H., Li, X., Guo, C., Yuan, F., Fisher, P. B., & Wang, X. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2142 · Cited by 40
Tartey, S., Neale, G. A. M., Vogel, P., Malireddi, R. K. S., & Kanneganti, T. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3510 · Cited by 40
Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma
Penny, H. L., Sieow, J. L., Gun, S. Y., Lau, M. C., Lee, B. T. K., Tan, J., Phua, C., Toh, F., Nga, Y., Yeap, W. H., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126350 · Cited by 40
Andreuzzi, E., Fejza, A., Polano, M., Poletto, E., Camicia, L., Carobolante, G., Tarticchio, G., Todaro, F., Carlo, E. D., Scarpa, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02271-y · Cited by 40
Yan, J., Wang, Z., Yang, H.-Z., Liu, H.-Z., Mi, S., Lv, X.-X., Fu, X.-M., Yan, H.-M., Zhang, X.-W., Zhan, Q., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024705 · Cited by 39
Self-citationLi, Y., Song, Y., Li, P., Li, M., Wang, H., Xu, T., Yu, X., Yu, Y., Tai, Y., Chen, P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000111 · Cited by 39
Moreno, V., Calvo, E., Middleton, M. R., Barlési, F., Gaudy‐Marqueste, C., Italiano, A., Romano, E., Marabelle, A., Chartash, E., Dobrenkov, K., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03191-8 · Cited by 39
Liu, Y., Sun, Q., Zhang, C., Ding, M., Wang, C., Zheng, Q., Ma, Z., Xu, H., Zhou, G., Wang, X., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107376 · Cited by 39
A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicronin vivo
Zuo, D., Chen, Y., Cai, J., Yuan, H.-Y., Wu, J., Yin, Y., Xie, J., Lin, J., Luo, J., Feng, Y., et al. (2022) · Protein & Cell · doi:10.1093/procel/pwac027 · Cited by 38
Chodisetti, S. B., Gowthaman, U., Rai, P. K., Vidyarthi, A., Khan, N., & Agrewala, J. N. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu472 · Cited by 36
Gowing, S. D., Chow, S. C., Cools‐Lartigue, J., Chen, C. B., Najmeh, S., Jiang, H. Y., Bourdeau, F., Beauchamp, A., Mancini, U., Angers, I., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30734 · Cited by 36
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine
Mai, J., Li, Z., Xia, X., Zhang, J., Li, J., Liu, H., Shen, J., Ramirez, M., Li, F., Li, Z., et al. (2021) · Advanced Science · doi:10.1002/advs.202100166 · Cited by 36
Jiang, H., Yu, K., Cui, Y., Ren, X., Li, M., Yang, C., Zhao, X., Zhu, Q., & Lin, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632547 · Cited by 36
Cited by
Huynh, T. M. H., Huang, P.-X., Wang, K.-L., Tran, N.-T., Iao, H. M., Pan, W.-C., Chang, Y.-H., Lien, H.-W., Lee, A. Y.-L., Chou, T.-C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c05395 · Cited by 122
Neutrophils and Neutrophil-Based Drug Delivery Systems in Anti-Cancer Therapy
Wahnou, H., El Kebbaj, R., Hba, S., Ouadghiri, Z., El Faqer, O., Pinon, A., Liagre, B., Limami, Y., & Duval, R. E. (2025) · Cancers · doi:10.3390/cancers17071232 · Cited by 35
Immunogenic cell death mediated TLR3/4-activated MSCs in U87 GBM cell line
Emami Meybodi, S. M., Moradi Moraddahande, F., & Dehghani Firoozabadi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29858 · Cited by 3
Metadata
- Authors
- Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-03-25
- Volume
- 9
- Issue
- 1
- Pages
- 68-68
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4394738965
- Cited by
- 255
- References
- 670
- FWCI
- 38.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.